Suven Life Sciences has announced its participation in the BIO International Convention 2026 (BIO-2026), taking place during June 22–25, 2026, in San Diego, USA.

The company will welcome the delegates, investors, and potential partners and collaborators from big pharma and biotech companies. It will showcase its differentiated CNS portfolio, including late-stage clinical assets targeting significant unmet medical needs in indications like agitation in dementia of Alzheimer's type, Major Depressive Disorder (MDD), narcolepsy, cognitive impairment associated with Parkinson's Disease (PD) and other CNS disorders.

The goal is to engage with global pharmaceutical and biotechnology companies to explore partnering strategies, out-licensing, and/or co-development initiatives for Suven clinical candidates through 62 pre-scheduled partnering meetings in 4 days of BIO-2026.

Venkat Jasti, Chairman and Managing Director, Suven Life Sciences, said, “BIO-2026 offers a valuable opportunity to highlight the meaningful advancements across our clinical pipeline and connect with potential partners who share our dedication to addressing unmet needs in CNS disorders. The positive phase 2b results for Ropanicant in Major Depressive Disorder, promising and favourble phase 1 data for SUVN-I6107, continued progress of our phase 3 programs, Masupirdine for agitation in Dementia of Alzheimer's type and Samelisant (AWAKE study) for narcolepsy, underscore the depth and maturity of our portfolio. We look forward to exploring strategic partnering and collaboration opportunities that can help accelerate the development and commercialisation of these assets.”